Tiplaxtinin

PAI-039 (tiplaxtinin) is an orally active, small-molecule inhibitor of Plasminogen Activator Inhibitor-1 (PAI-1). PAI-1 is a member of the serpin superfamily and acts as the primary physiological inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), thereby playing a critical role in regulating fibrinolysis and extracellular matrix remodeling. By binding to PAI-1, PAI-039 prevents its interaction with these plasminogen activators, leading to increased plasmin generation and subsequent degradation of fibrin and other matrix proteins. Originally developed by Wyeth for metabolic conditions such as obesity and metabolic syndrome, PAI-039 has more recently been explored for its potential to treat fibrotic and inflammatory disorders, including sclerodermatous chronic graft-versus-host disease (cGVHD). Preclinical studies indicate that PAI-039 can reduce pro-inflammatory cytokine levels and attenuate tissue fibrosis, suggesting a therapeutic role in disrupting pathogenic fibrotic signaling.

Other names

PAI-039PAI039PAI 039Tiplaxtinin